A Cross-Sectional Study on Single-Day Use of Proton Pump Inhibitors in Tertiary Care Hospitals of South India

Overview

Journal Hosp Pharm

Publisher Sage Publications

Date 2021 Apr 1

PMID 33790486

Citations 1

Authors

Zabiuddin Ahad M

Alekhya Lavu

Maria Ansari

Raviraj Acharya V

Rajesh Vilakkathala

Affiliations

Soon will be listed here.

Abstract

Proton pump inhibitors (PPIs) are the most potent antacids used in clinical practice with greater safety and efficacy. Limited data are available on the usage of PPIs in Indian health-care settings. Our aim was to understand the usage pattern and potential drug interactions with concurrently administered medications employing a single-day cross-sectional study design. A prospective observational cross-sectional study conducted on a single day, at two tertiary care teaching hospitals in South India. Inpatients of above 18 years of age were included. Case profiles were reviewed and data were collected in predesigned forms and analyzed. Drug interactions were identified using Micromedex and Medscape drug-interaction databases. A total of 797 case profiles screened from both the centers; 714 were prescribed with PPIs. In intensive care units (ICUs), the use of PPIs was highest with 95% of cases getting these drugs. A PPI was seen in about 93% of patients, who had more than or equal to 4 drugs in their prescriptions. Pantoprazole was the mostly prescribed PPI in around 90% of the cases. Around 33% of the PPIs usage was through IV (intravenous) route, and 75% of that use was seen in wards. Around 134 drug interactions were identified, of which 10 were of major severity. Around 90% of inpatients were prescribed with PPIs. Pantoprazole is the most commonly prescribed PPI (90%). The IV administration was seen more in wards than ICUs, and 10 major drug interactions were observed in this single-day study. Careful monitoring is needed to avoid serious drug interactions involving PPIs, and training programs should sensitize the clinicians on the evidence-based use of PPIs.

Citing Articles

High Dose Pantoprazole for Gastroesophageal Reflux Disease: Need, Evidence, Guidelines and Our Experience.

Upadhyay R, Soni N, Kotamkar A, Naseem A, Phadke A, Nayar S Euroasian J Hepatogastroenterol. 2024; 14(1):86-91.

PMID: 39022196 PMC: 11249892. DOI: 10.5005/jp-journals-10018-1426.

References

Nasser S, Nassif J, Dimassi H . Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients. World J Gastroenterol. 2010; 16(8):982-6. PMC: 2828603. DOI: 10.3748/wjg.v16.i8.982. View

Pasina L, Nobili A, Tettamanti M, Salerno F, Corrao S, Marengoni A . Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med. 2011; 22(2):205-10. DOI: 10.1016/j.ejim.2010.11.009. View

Ahrens D, Chenot J, Behrens G, Grimmsmann T, Kochen M . Appropriateness of treatment recommendations for PPI in hospital discharge letters. Eur J Clin Pharmacol. 2010; 66(12):1265-71. PMC: 2982961. DOI: 10.1007/s00228-010-0871-9. View

Setia M . Methodology Series Module 3: Cross-sectional Studies. Indian J Dermatol. 2016; 61(3):261-4. PMC: 4885177. DOI: 10.4103/0019-5154.182410. View

Bezabeh S, Mackey A, Kluetz P, Jappar D, Korvick J . Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors. Oncologist. 2012; 17(4):550-4. PMC: 3336837. DOI: 10.1634/theoncologist.2011-0431. View

Zink D, Pohlman M, Barnes M, Cannon M . Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther. 2005; 21(10):1203-9. DOI: 10.1111/j.1365-2036.2005.02454.x. View

Scarpignato C, Gatta L, Zullo A, Blandizzi C . Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016; 14(1):179. PMC: 5101793. DOI: 10.1186/s12916-016-0718-z. View

BAMBERG P, Caswell C, Frame M, Lam S, Wong E . A meta-analysis comparing the efficacy of omeprazole with H2-receptor antagonists for acute treatment of duodenal ulcer in Asian patients. J Gastroenterol Hepatol. 1992; 7(6):577-85. DOI: 10.1111/j.1440-1746.1992.tb01489.x. View

Hungin A, Rubin G, OFlanagan H . Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract. 1999; 49(443):451-3. PMC: 1313442. View

10.

Stockl K, Le L, Zakharyan A, Harada A, Solow B, Addiego J . Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med. 2010; 170(8):704-10. DOI: 10.1001/archinternmed.2010.34. View

11.

Ansari J . Drug interaction and pharmacist. J Young Pharm. 2010; 2(3):326-31. PMC: 2964764. DOI: 10.4103/0975-1483.66807. View

12.

Nikfar S, Abdollahi M, Moretti M, Magee L, Koren G . Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. Dig Dis Sci. 2002; 47(7):1526-9. DOI: 10.1023/a:1015863018105. View

13.

Lalkin A, Loebstein R, Addis A, Mastroiacovo P, Mazzone T, Vial T . The safety of omeprazole during pregnancy: a multicenter prospective controlled study. Am J Obstet Gynecol. 1998; 179(3 Pt 1):727-30. DOI: 10.1016/s0002-9378(98)70072-9. View

14.

Brewster U, Perazella M . Acute kidney injury following proton pump inhibitor therapy. Kidney Int. 2006; 71(6):589-93. DOI: 10.1038/sj.ki.5002038. View

15.

Kelly O, Dillane C, Patchett S, Harewood G, Murray F . The Inappropriate Prescription of Oral Proton Pump Inhibitors in the Hospital Setting: A Prospective Cross-Sectional Study. Dig Dis Sci. 2015; 60(8):2280-6. DOI: 10.1007/s10620-015-3642-8. View

16.

Mat Saad A, Collins N, Lobo M, OConnor H . Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract. 2005; 59(1):31-4. DOI: 10.1111/j.1742-1241.2004.00298.x. View

17.

Kheshti R, Aalipour M, Namazi S . A comparison of five common drug-drug interaction software programs regarding accuracy and comprehensiveness. J Res Pharm Pract. 2016; 5(4):257-263. PMC: 5084483. DOI: 10.4103/2279-042X.192461. View

18.

Voukelatou P, Vrettos I, Emmanouilidou G, Dodos K, Skotsimara G, Kontogeorgou D . Predictors of Inappropriate Proton Pump Inhibitors Use in Elderly Patients. Curr Gerontol Geriatr Res. 2019; 2019:7591045. PMC: 6333003. DOI: 10.1155/2019/7591045. View

19.

Meyer U . Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Yale J Biol Med. 1996; 69(3):203-9. PMC: 2589004. View

20.

Ali T, Roberts D, Tierney W . Long-term safety concerns with proton pump inhibitors. Am J Med. 2009; 122(10):896-903. DOI: 10.1016/j.amjmed.2009.04.014. View